Close Menu

NEW YORK – T2 Biosystems disclosed in a filing with the Securities and Exchange Commission on Wednesday it received a warning letter from the Nasdaq Stock Market because its stock price has been below $1 for at least 30 consecutive business days.

As a result, the company could face delisting action by Nasdaq. T2 Bio has until Oct. 5 to avoid delisting, and the firm said it will monitor the bid price of its common stock and consider potential options, including performing a reverse stock split.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.